{"id":"W1992008940","doi":"10.1097/qad.0b013e32832d3b54","title":"Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy","year":2009,"lang":"en","type":"article","venue":"AIDS","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Gilead Sciences; GlaxoSmithKline; Bristol-Myers Squibb; Medical Research Council; Abbott Laboratories; European Commission; Pfizer; National Institutes of Health; National Science Foundation","keywords":"Nevirapine; Antiretroviral therapy; Medicine; Limiting; Oncology; Virology; Internal medicine; Intensive care medicine; Human immunodeficiency virus (HIV); Pharmacology; Viral load","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002069275,0.0003258286,0.000556738,0.0005395917,0.0003962421,0.0008080513,0.000444741,0.0004245095,0.0008105487],"category_scores_gemma":[0.00510746,0.0003231646,0.0009497187,0.000771652,0.000181107,0.0002973146,0.0005616444,0.000698464,0.0001066038],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003656883,"about_ca_system_score_gemma":0.0007509621,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002907477,"about_ca_topic_score_gemma":0.003366094,"domain_scores_codex":[0.9989109,0.000405109,0.0001253135,0.000202222,0.0002371636,0.0001192531],"domain_scores_gemma":[0.9943989,0.001297529,0.003207619,0.000332663,0.0002917231,0.0004715679],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001600531,0.00002466623,0.9991359,0.000005743995,0.00008523051,0.00001290084,0.000015412,0.00002446751,0.00003044844,0.000004173723,0.00002825533,0.0004728224],"study_design_scores_gemma":[0.00004990721,0.0001938833,0.9990182,0.000008327591,0.00009004226,0.0001584089,0.00004455469,0.0002428977,0.00004994125,0.00001727327,0.0001232463,0.000003321464],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9990497,0.0002834659,0.0001064191,0.00001977721,0.000004720164,0.0000208509,0.000356396,0.000002837718,0.0001557715],"genre_scores_gemma":[0.9988025,0.000144469,0.0001745987,0.00002405287,0.00001439488,0.00002706878,0.0007378236,0.000001614347,0.00007340459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002907477,"threshold_uncertainty_score":0.01094353,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0242688332906109,"score_gpt":0.2753207164001895,"score_spread":0.2510518831095785,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}